Physician profile
Matthew Charles Altman
NPI 1518195999
$36,858.06
in general payments reported to CMS, 2019-2025
8 companies · $24K in 2025
The $24K reported for 2025 was more than what 95% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,888 · 2020: $2,481 · 2022: $126 · 2024: $360 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Travel and Lodging: $1,180 · Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,695.00 |
| Travel and Lodging | $1,180.35 |
| Food and Beverage | $487.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14,614.04 | 2025 | |
| Genzyme Corporation | $12,322.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $8,020.86 | 2024-2025 | Nucala |
| Astrazeneca Pharmaceuticals Lp | $1,689.30 | 2022-2025 | Fasenra |
| Pharming Healthcare, INC. | $125.68 | 2024 | |
| Blueprint Medicines Corporation | $38.71 | 2024 | Ayvakit |
| Csl Behring | $26.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Altman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.